ALLIANCE AND BUSINESS DEVELOPMENT

As an integrated organisation with R&D, Manufacturing and Marketing & Distribution capabilities, C&O offers local and international pharmaceutical companies a reliable one-stop service for partners to tap into China’s competitive resources and large market potential swiftly.

Our growth strategy also focuses on collaborations and partnerships with overseas partners to expand our range of foreign imported products by securing sole distributorship rights and expand our R&D portfolio by technology transfer.

Distribution of pharmaceutical and healthcare products

Our ability to secure long-term exclusive distribution rights on several imported drugs is a clear endorsement of our distribution prowess. Coupled with our import/export licence, we are well-positioned to provide distribution services for local and international drug companies.

CRO Services

Since 2003, C&O has been providing contract research (CRO) services to local and international pharmaceutical companies seeking to outsource their R&D activities. Today, we are one of the leading pharmaceutical companies in China with approximately 120 in-house researchers, who have been handpicked for their specialties in different fields, covering chemical synthesis, drug formulation and preparation methods, clinical research & product registration, manufacturing techniques and pharmaceutical analysis. We have a strong pipeline of drugs addressing acute medical areas such as anti-infective, anti-HBV, anti-cancer, anti-tuberculous, anti-aging and anti-obesity. Three potential patent drugs are also under development.

Apart from having research talents with the right skills, we are gearing up our R&D capabilities with modern equipment and facilities. We are in the midst of constructing a new R&D centre in Nanjing and upgrading our R&D centre in Shanghai.

CMO Services

Since 2000, we have been providing contract manufacturing (CMO) services to local and international pharmaceutical companies seeking to outsource their production using our GMP-certified manufacturing facilities. Our 13 productions processes are capable of manufacturing a wide array of formulations, including tablets, capsules, ointment, granules, gelatine, cream, freeze-dried powders for injection and active pharmaceutical ingredients (API).

Our facilities occupy a site area of approximately 60,000 sq metres with a total gross floor area of over 20,000 sq metres. Supported by modernised systems, all stages of our manufacturing processes are operated by qualified pharmaceutical and engineering professionals to ensure the highest possible standards in production, inventory and quality controls as well as packaging.

As quality assurance is of utmost importance to C&O, we ensure that our products meet the stringent regulatory requirements before delivery to our customers.

Areas of cooperation

The areas of cooperation are non-exhaustive and include i) sharing of information on pre-clinical and clinical research work for products in the pipeline; ii) collaboration in the screening and synthesis of new chemical compounds with therapeutic properties; iii) CRO services; (iv) technology transfer; v) CMO services vi) cooperation on in-licensing and out-licensing of pharmaceutical and healthcare products and vii) sharing of market intelligence.


If you are interested to become our business partner, please contact:

C & O Pharmaceutical Technology (Holdings) Limited

Principal office in Hong Kong:

911-12 Silvercord Tower 2,
30 Canton Road,
Tsim Sha Tsui,
Kowloon,
Hong Kong.


Email:
yoshiaki.miyamoto@changao.com.hk


Page Updated as at 12/07/13